| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Amifostine (Ethyol®): Dosing, administration and patient management guidelines
|
Bukowski, R.M.
|
|
1996
|
32 |
S4 |
p. S46-S49
4 p.
|
artikel
|
| 2 |
Amifostine (Ethyol®): Pharmacokinetic and Pharmacodynamic Effects in vivo
|
Vijgh, W.J.F. van der
|
|
1996
|
32 |
S4 |
p. S26-S30
5 p.
|
artikel
|
| 3 |
Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, in vitro
|
Dorr, R.T.
|
|
1996
|
32 |
S4 |
p. S21-S25
5 p.
|
artikel
|
| 4 |
Clinical effects of amifostine (Ethyol®) in patients treated with carboplatin
|
Budd, G.T.
|
|
1996
|
32 |
S4 |
p. S43-S45
3 p.
|
artikel
|
| 5 |
Current Approaches in Cytoprotection: the Role of Amifostine (Ethyol®) in Altering and Ameliorating Toxicities in Cancer Therapy
|
Bukowski, R.M.
|
|
1996
|
32 |
S4 |
p. S1-
1 p.
|
artikel
|
| 6 |
Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol®)
|
Schuchter, L.M.
|
|
1996
|
32 |
S4 |
p. S40-S42
3 p.
|
artikel
|
| 7 |
The need for cytoprotection
|
Bukowski, R.M.
|
|
1996
|
32 |
S4 |
p. S2-S4
3 p.
|
artikel
|
| 8 |
The potential role of amifostine (Ethyol®) in haematological malignancies
|
Gorin, N.C.
|
|
1996
|
32 |
S4 |
p. S31-S39
9 p.
|
artikel
|
| 9 |
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®)
|
Capizzi, R.L.
|
|
1996
|
32 |
S4 |
p. S5-S16
12 p.
|
artikel
|
| 10 |
WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
|
Alberts, D.S.
|
|
1996
|
32 |
S4 |
p. S17-S20
4 p.
|
artikel
|
Tijdschrift beschrijving